Literature DB >> 12488058

Decrease in genu of the corpus callosum in medication-naïve, early-onset dysthymia and depressive personality disorder.

In Kyoon Lyoo1, Jun Soo Kwon, Soo Jin Lee, Moon Hee Han, Chang-Gok Chang, Cheon Seok Seo, Sang Ik Lee, Perry F Renshaw.   

Abstract

BACKGROUND: The purpose of this study was to detect differences in regional areas of the corpus callosum (CC) in subjects with early-onset minor depression (dysthymia or depressive personality disorder) and healthy comparison subjects. Based on previous reports that have suggested reduced frontal lobe volume and reduced hemispheric lateralization in the frontal regions of the brain in depression, we hypothesized that the area of the CC that interconnects the frontal regions of the brain, i.e., the genu, will be smaller compared to that of healthy comparison subjects.
METHODS: Forty female subjects with early-onset dysthymia or depressive personality disorder, as defined by the Structured Clinical Interview for DSM-III-R and the Diagnostic Interview for Depressive Personality, respectively, and age- and gender-matched healthy comparison subjects (n = 42) were recruited (age: 21.4 +/- 2.1 and 20.9 +/- 2.8 years, respectively). All subjects were psychotropic medications-naïve and right-handed. A 1.5T GE Sigma scanner was used to acquire 124 1.5-mm-thick contiguous coronal images. Midsagittal slice images were carefully selected from reconstructed magnetic resonance images both from native and stereotaxic space to measure seven regional areas of the CC.
RESULTS: There were significant diagnosis by CC region interactions [F(6,480) = 4.06, p <.001; F(6,480) = 3.30, p =.003, native and stereotaxic space, respectively]. Early-onset minor depression subjects had a 9.9% (native space) and 6.9% (stereotaxic space) smaller genu of the CC compared to the healthy comparison subjects (the Newman-Keuls post hoc test, p =.005 and.019, native and stereotaxic space, respectively). Early-onset minor depression subjects also had a 7.8% smaller posterior midbody relative to the comparison subjects (the Newman-Keuls post hoc test, p =.033) only in the native space. Severity of current depressive symptoms or duration of illness did not correlate with the size of the genu or the posterior midbody parts of the CC.
CONCLUSIONS: These results suggest frontal lobe structural, and possibly functional, abnormalities in the brain in young female adults with a milder spectrum of depression, i.e., DSM-IV early-onset dysthymia or depressive personality disorder. The present findings point out the possible role of frontal lobe abnormality in pathophysiology of early-onset minor depression.

Entities:  

Mesh:

Year:  2002        PMID: 12488058     DOI: 10.1016/s0006-3223(02)01436-1

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  12 in total

1.  Software pipeline for midsagittal corpus callosum thickness profile processing : automated segmentation, manual editor, thickness profile generator, group-wise statistical comparison and results display.

Authors:  Chris Adamson; Richard Beare; Mark Walterfang; Marc Seal
Journal:  Neuroinformatics       Date:  2014-10

2.  Rare case of glioblastoma multiforme located in posterior corpus callosum presenting with depressive symptoms and visual memory deficits.

Authors:  Hale Yapıcı-Eser; Aslıhan Onay; Özgür Öztop-Çakmak; Emrah Egemen; Ebru Nur Vanlı-Yavuz; İhsan Solaroğlu
Journal:  BMJ Case Rep       Date:  2016-12-15

3.  Antidepressants normalize the default mode network in patients with dysthymia.

Authors:  Jonathan Posner; David J Hellerstein; Inbal Gat; Anna Mechling; Kristin Klahr; Zhishun Wang; Patrick J McGrath; Jonathan W Stewart; Bradley S Peterson
Journal:  JAMA Psychiatry       Date:  2013-04       Impact factor: 21.596

4.  Mapping callosal morphology in early- and late-onset elderly depression: an index of distinct changes in cortical connectivity.

Authors:  Martina Ballmaier; Anand Kumar; Virginia Elderkin-Thompson; Katherine L Narr; Eileen Luders; Paul M Thompson; Cornelius Hojatkashani; Daniel Pham; Andreas Heinz; Arthur W Toga
Journal:  Neuropsychopharmacology       Date:  2007-08-22       Impact factor: 7.853

Review 5.  Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors:  Jonathan Savitz; Wayne C Drevets
Journal:  Neurosci Biobehav Rev       Date:  2009-01-21       Impact factor: 8.989

6.  Omega-3 polyunsaturated fatty acid supplementation and white matter changes in major depression.

Authors:  Binod Thapa Chhetry; Adrienne Hezghia; Jeffrey M Miller; Seonjoo Lee; Harry Rubin-Falcone; Thomas B Cooper; Maria A Oquendo; J John Mann; M Elizabeth Sublette
Journal:  J Psychiatr Res       Date:  2016-01-11       Impact factor: 4.791

7.  Atrophic Corpus Callosum Associated with Altered Functional Asymmetry in Major Depressive Disorder.

Authors:  Shuhua Ran; Zhiwei Zuo; Chang Li; Xuntao Yin; Wei Qu; Qianying Tang; Yao Wang; Yanshu Shi; Haitao Li
Journal:  Neuropsychiatr Dis Treat       Date:  2020-06-10       Impact factor: 2.570

8.  A preliminary study of white matter in adolescent depression: relationships with illness severity, anhedonia, and irritability.

Authors:  Sarah E Henderson; Amy R Johnson; Ana I Vallejo; Lev Katz; Edmund Wong; Vilma Gabbay
Journal:  Front Psychiatry       Date:  2013-11-25       Impact factor: 4.157

9.  Corpus callosum size is highly heritable in humans, and may reflect distinct genetic influences on ventral and rostral regions.

Authors:  Girma Woldehawariat; Pedro E Martinez; Peter Hauser; David M Hoover; Wayne W C Drevets; Francis J McMahon
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  Association between reduced white matter integrity in the corpus callosum and serotonin transporter gene DNA methylation in medication-naive patients with major depressive disorder.

Authors:  E Won; S Choi; J Kang; A Kim; K-M Han; H S Chang; W S Tae; K R Son; S-H Joe; M-S Lee; B-J Ham
Journal:  Transl Psychiatry       Date:  2016-08-09       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.